Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

计划入组 20 人 · 首次发布于 2015 年 7 月 8 日

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

计划入组 50 人 · 首次发布于 2015 年 7 月 31 日

Itacitinib for Low Risk GVHD

计划入组 70 人 · 首次发布于 2019 年 2 月 19 日

Graft vs. Host Disease(Aegle)

Graft-versus-host disease therapeutics (Mallinckrodt)

Graft-versus-host disease therapy(Applied StemCell, Inc.)

Vascular Graft Solutions Ltd.

Israel

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

FDA Approves Axatilamab for Chronic Graft-versus-Host Disease After Breakthrough Discovery

NCCN Guidelines Update: Evolving Treatment Landscape for Graft-vs-Host Disease Management

European Regulators Reject Sanofi's Rezurock for Chronic Graft-vs-Host Disease Treatment